Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy

Nuclear Medicine and Biology

Volumn 35, Issue SUPPL.1, 2008, Pages

  Mairs, Rob J ^a   Boyd, Marie ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Bystander effects; Combination therapy; No carrier added 131I MIBG

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ASTATINE 211; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DOXORUBICIN; GAMMA INTERFERON; IODINE 131; PHORBOL ESTER; TOPOTECAN;

CANCER INHIBITION; CELL KILLING; CYTOTOXICITY; DNA REPAIR; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; HUMAN; ISOTOPE LABELING; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; RADIATION DOSE; RADIATION INJURY; REVIEW; TUMOR GROWTH;

3-IODOBENZYLGUANIDINE; BYSTANDER EFFECT; COMBINED MODALITY THERAPY; HUMANS; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TOPOTECAN;

EID: 49049098815     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.04.008     Document Type: Review

References (105)

1. Garaventa A., Guerra P., Arrighini A., Bertolazzi L., Bestagno M., De Bernardi B., et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanide. Cancer 67 (1991) 922-928
2. 131I-meta-iodobenzylguanidine in patients with neuroblastoma. Future prospects of zetotherapy. In: Evans A.E., D'Angio G.J., Knudson A.G., and Seeger R.C. (Eds). Advances in neuroblastoma research. 3rd ed. (1991), Wiley-Liss, New York 439-445
3. Lashford L.S., Lewis I.J., Fielding S.L., Flower M.A., Meller S., Kemshead J.T., et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 10 (1992) 1889-1896
4. 131I-MIBG). Ann NY Acad Sci 1073 (2006) 465-490
5. Matthay K.K., Yanik G., Messina J., Quach A., Huberty J., Cheng S.C., et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25 (2007) 1054-1060
6. Smets L.A., Loesberg C., Janssen M., Metwally E.A., and Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 49 (1989) 2941-2944
7. 131I-mIBG: evaluation of a novel preparation of a therapeutic radiopharmaceutical. J Nucl Med 36 (1995) 1088-1095
8. 131I-meta-iodo-benzyl guanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Brit J Cancer 70 (1994) 97-101
9. 131I]meta-iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 9 (2003) 3338-3344
10. 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20 (2005) 195-199
11. Wangberg B., Muth A., Khorram-Manesh A., Jansson S., Nilsson O., Forssell-Aronsson E., et al. Malignant pheochromocytoma in a population-based study. Ann N Y Acad Sci 1073 (2006) 512-516
12. Matthay K.K., Tan J.C., Villablanca J.G., Yanik G.A., Veatch J., Franc B., et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24 (2006) 500-506
13. 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98 (2003) 239-248
14. Mangner J.T., Wu J.L., and Wieland D.M. Solid-phase exchange radioiodination of aryl iodides: facilitation by ammonium sulfate. J Org Chem 47 (1982) 1484-1488
15. 131I]iodobenzylguanidine. Appl Radiat Isot 44 (1993) 621-628
16. 131I]iodobenzylguanidine in patients. Cancer Res 47 (1987) 6147-6149
17. 131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity. Brit J Cancer 73 (1996) 1171-1177
18. Babich J.W., Graham W., and Fischman A.J. Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells. Eur J Nucl Med 24 (1997) 538-543
19. 123I]MIBG. J Lab Comp Radiopharm 42 (1999) 653-661
20. 211At]MABG. J Label Compd Radiopharm 50 (2007) 177-182
21. 125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO. Cancer Res 48 (1988) 2993-2997
22. 123I]MIBG in rats. Nucl Med Commun 9 (1988) 663-667
23. 123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity. Eur J Nucl Med Mol Imag 33 (2006) 483-490
24. Farahati J., Bier D., Scheubeck M., Lassmann M., Schelper L.P., Grelle I., et al. Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med 38 (1997) 447-451
25. 131I]MIBG in xenografted BALB/c nu/nu mice. In: Evans A.E., Biedler J.L., Brodeur G.M., D'Angio G.J., and Nakagawara A. (Eds). Advances in neuroblastoma research. 4th ed. (1994), Wiley-Liss, New York 446-453
26. 131I-meta-iodo-benzyl guanidine in two neuroblastoma xenografts. Brit J Radiol 67 (1994) 573-578
27. 131I-MIBG: implications for the radiotherapy of neuroblastoma. Eur J Cancer 31 (1995) 576-581
28. 131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene. Lett Drug Des Disc 1 (2004) 50-57
29. 123I]iodobenzylguanidine: synthesis and preliminary evaluation. Nucl Med Biol 22 (1995) 61-64
30. Rutgers M., Buitenhuis C.K., Hoefnagel C.A., Voute P.A., and Smets L.A. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy. Int J Cancer 87 (2000) 412-422
31. Fredrikson M., Hursti T.J., Steineck G., Furst C.J., Borjesson S., and Peterson C. Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer 70 (1994) 642-645
32. 131I-meta-iodobenzylguanidine. Eur J Nucl Med Mol Imag 14 (1988) 337-340
33. Bongers V., de Klerk J.M.H., Zonnenberg B.A., de Kort G., Lips C.J.M., and van Rijk P.P. Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumors. J Nucl Med 38 (1997) 1024-1026
34. 131I]MIBG in a child with neuroblastoma. Oral Med Oral Surg Oral Pathol Oral Radiol Endodont 92 (2001) 420-423
35. Mairs R.J., and Zalutsky M.R. New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment. Brit J Cancer 72 (1995) 250
36. 123I]mIBG: an initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 21 (2000) 437-440
37. 123I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med 27 (2000) 302-307
38. 123I]iodobenzylguanidine in clinical studies II. Eur J Nucl Med 28 (2001) 941
39. O'Donoghue J.A., Bardies M., and Wheldon T.E. Relationships between tumour size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36 (1995) 1902-1909
40. Armour A., Cunningham S.H., Gaze M.N., Wheldon T.E., and Mairs R.J. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer 75 (1997) 470-476
41. Smets L.A., Janssen M., Rutgers M., Ritzen K., and Buitenhuis C. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells. Int J Cancer 48 (1991) 609-615
42. Montaldo P.G., Carbone R., Ponzoni M., and Cornaglia-Ferraris P. γ-Interferon increases metaiodobenzylguanidine incorporation and retention in human neuroblastoma cells. Cancer Res 52 (1992) 4960-4964
43. Montaldo P.G., Raffaghello L., Guarnaccia F., Pistoia V., Garaventa A., and Ponzoni M. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer 67 (1996) 95-100
44. Hopfner M., Sutter A.P., Huether A., Ahnert-Hilger G., and Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine. BMC Cancer 4 (2004) 23-37
45. Mairs R.J., and Wheldon T.E. Experimental tumour therapy with targeted radionuclides in multicellular tumour spheroids. In: Hagen U., Harder D., Jung H., and Streffer C. (Eds). Radiation research 1895-1995; Congress proceedings Vol. 2. (1996), Universitatsdruckerei, H. Sturtz AG, Wurtzburg 819-826
46. Meco D., Lasorella A., Riccardi A., Servidei T., Mastrangelo R., and Riccardi R. Influence of cisplatin and doxorubicin on I-125-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 35 (1999) 1227-1234
47. Vassal G., Pondarré C., Capelli C., Terrier-Lacombe M.J., Boland I., Morizet J., et al. DNA-topoisomerase I, a new target for the treatment of neuroblastoma. Eur J Cancer 33 (1997) 2011-2015
48. Nitschke R., Parkhurst J., Sullivan J., Harris M.B., Bernstein M., and Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumours: a Pediatric Oncology Group Phase II study. J Ped Hematol Oncol 20 (1998) 315-318
49. 131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma. Cancer Letters 228 (2005) 221-227
50. Miyamoto S., Huang T.T., Wuerzberger-Davis S., Bornmann W.G., Pink J.J., Tagliarino C., et al. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann N Y Acad Sci 922 (2000) 274-292
51. Mattern M.R., Hofmann G.A., McCabe F.L., and Johnson R.K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK and F 104864). Cancer Res 51 (1991) 5813-5816
52. Boscia R.E., Korbut T., Holden S.A., Ara G., and Teicher B.A. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSaIIC fibrosarcoma in vivo. Int J Cancer 53 (1993) 118-123
53. Hennequin C., Giocanti N., Balosso J., and Favaudon V. Interaction of ionising radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 54 (1994) 1720-1728
54. Marchesini R., Colombo A., and Caserini C. Interaction of ionizing radiation with topotecan in two human cell lines. Int J Cancer 66 (1996) 342-346
55. Lamond J.P., Wang M., Kinsella T.J., and Boothman D.A. Concentration and timing dependence enhancement between topotecan, a topoisomerase I inhibitor and ionising radiation. Int J Radiat Oncol Biol Phys 36 (1996) 361-368
56. Kohara H., Tabata M., Kiura K., Ueoka H., Kawata K., Chikamori M., et al. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin Cancer Res 8 (2002) 287-292
57. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
58. Chou T.C. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou T.C., and Rideout D.C. (Eds). Synergism and antagonism in chemotherapy (1991), Academic Press, New York 61-102
59. Livingstone A., Mairs R.J., Russell J., O'Donoghue J., Gaze M.N., and Wheldon T.E. N-myc gene copy number in neuroblastoma cell lines and resistance to experimental treatment. Eur J Cancer 30 (1994) 382-389
60. Boyd M., Livingstone A., Wilson L.E., Marshall E.M., McCluskey A.G., Mairs R.J., et al. The dose response relationship for radiation induced mutations at micro- and minisatellite loci in human somatic cells in culture. Int J Radiat Biol 76 (2000) 169-176
61. 131I]meta-iodobenzylguanidine and topotecan in combination. Br J Radiol (2008) [in press]
62. 131I]meta-Iodobenzylguanidine and topotecan combination treatment of tumours expressing the noradrenaline transporter. Clin Can Res 11 (2005) 7929-7937
63. Donfrancesco A., Jenkner A., Castellano A., Ilari I., Milano G.M., De Sio L., et al. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Int J Paediatr 93 (2004) 6-11
64. Keshelava N., Groshen S., and Reynolds P. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 45 (2000) 1-8
65. Dubois S.G., Messina J., Maris J.M., Huberty J., Glidden D.V., Veatch J., et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 22 (2004) 2452-2460
66. Kramer K., Kushner B.H., and Cheung N.K.V. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Ped Hematol Oncol 25 (2003) 601-605
67. Yanik G.A., Levine J.E., Matthay K.K., Sisson J.C., Shulkin B.L., Shapiro B., et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20 (2002) 2142-2149
68. 90Y. Radiother Oncol 21 (1991) 91-99
69. Humm J.L. Dosimetric aspects of radiolabelled antibodies for tumour therapy. J Nucl Med 27 (1986) 1490-1497
70. 131I]meta-Iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 66 (1992) 1048-1052
71. Cunningham S.H., Mairs R.J., Wheldon T.E., Welsh P.C., Vaidyanathan G., and Zalutsky M.R. Radiotoxicity to neuroblastoma cells and spheroids of beta-, alpha- and Auger electron-emitting conjugates of benzylguanidine. Br J Cancer 77 (1998) 2061-2068
72. Neshasteh-Riz A., Angerson W.J., Reeves J.R., Smith G., Rampling R., and Mairs R.J. Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using auger electron emitters. Br J Cancer 75 (1997) 493-499
73. Neshasteh-Riz A., Mairs R.J., Angerson W.J., Stanton P.D., Reeves J.R., Rampling R., et al. The implications of proliferative heterogeneity for the design of DNA-targeted radiotherapy: differential cytotoxicity of alternative radioiodoanalogues of IUdR to human glioma cells in monolayer or spheroid culture. Br J Cancer 77 (1998) 385-390
74. Zalutsky M.R., and Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha particle therapy. Curr Pharm Des 6 (2000) 1433-1455
75. 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49 (2008) 30-38
76. 211At]Astatobenzyl)-guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconj Chem 3 (1992) 499-503
77. 211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res 54 (1994) 5414-5419
78. 211At]Astatobenzylguanidine: further evaluation of a potential therapeutic agent. Int J Cancer 57 (1994) 908-913
79. 211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. J Neurooncol 25 (1995) 9-17
80. 211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Nucl Med Biol 23 (1996) 851-856
81. 211At]Astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. Br J Cancer 76 (1997) 226-233
82. Cunningham S.H., Mairs R.J., Wheldon T.E., Welsh P.C., Vaidyanathan G., and Zalutsky M.R. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 77 (1998) 2061-2068
83. Boyd M., Mairs R.J., Keith W.N., Ross S.C., Welsh P., Akabani G., et al. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Med 6 (2004) 937-947
84. Fullerton N.E., Boyd M., Ross S.C., Pimlott S.L., Babich J., Kirk D., et al. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. Med Chem 1 (2005) 611-618
85. Boyd M., Ross S.C., Dorrens J., Fullerton N.E., Tan K.W., Zalutsky M.R., et al. Radiation induced biological bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha, beta and Auger electron emitting radionuclides. J Nucl Med 47 (2006) 1007-1015
86. McCarthy H.O., Worthington J., Barrett E., Cosimo E., Boyd M., Mairs R.J., et al. p21(WAF-1)-mediated transcriptional targeting of iNOS gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 14 (2007) 246-255
87. 125I]-iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. Cancer Res 56 (1996) 5428-5434
88. 123I]Iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of hematopoietic lineage. Nucl Med Commun 25 (2004) 1125-1130
89. Vaidyanathan G., Welsh P.C., Vitorello K.C., Snyder S., Friedman H.S., and Zalutsky M.R. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. Eur J Nucl Med Mol Imag 31 (2004) 1362-1370
90. Vaidyanathan G., Affleck D.J., Alston K.L., Welsh P., and Zalutsky M.R. Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. Nucl Med Commun 25 (2004) 947-955
91. Vaidyanathan G., Affleck D.J., Norman J., O'Dorisio S., and Zalutsky M.R. A radioiodinated MEBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells. Bioconjug Chem 18 (2007) 2122-2130
92. Mothersill C., and Seymour C.B. Radiation induced bystander effects: past history and future directions. Radiat Res 155 (2001) 759-767
93. Mothersill C., and Seymour C.B. Radiation-induced bystander effects - implications for cancer. Nat Rev Cancer 4 (2004) 158-164
94. Lyng F.M., Seymour C.B., and Mothersill C. Early events in the apoptotic cascade initiated in cells treated with medium from the progeny of irradiated cells. Radiat Prot Dosim 99 (2002) 169-172
95. Lorimore S.A., and Wright E.G. Radiation-induced genomic instability and bystander effects: related inflammatory-type responses to radiation-induced stress and injury? A review. Int J Radiat Biol 79 (2003) 15-25
96. Morgan W.F. Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation?. Oncogene 22 (2003) 7094-7099
97. Little J.B. Genomic instability and bystander effects: a historical perspective. Oncogene 22 (2003) 6978-6987
98. Carlsson J., Aronsson E.F., Hietala S.-O., Stigbrand T., and Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66 (2003) 107-117
99. Xue L.Y., Butler N.J., Makrigiorgos G.M., Adelstein S.J., and Kassis A.I. Bystander effect produced by radiolabelled tumour cells in vivo. Proc Natl Acad Sci U S A 99 (2002) 13765-13770
100. Kassis A.I. In vivo validation of the bystander effect. Hum Exp Toxicol 23 (2004) 71-73
101. Bishayee A., Hill H.Z., Stein D., Rao D.V., and Howell R.W. Free radical-initiated and gap junction-mediated bystander effect due to nonuniform distribution of incorporated radioactivity in a three-dimensional tissue culture model. Radiat Res 155 (2001) 335-344
102. Mothersill C., and Seymour C.B. Medium from irradiated human epithelial cells but not human fibroblasts reduced clonogenic survival of unirradiated cells. Int J Radiat Biol 71 (1997) 421-427
103. Seymour C.B., and Mothersill C. Relative contribution and targeted cell killing to the low-dose region of the radiation dose-response curve. Radiat Res 153 (2000) 508-511
104. Belyakov O.V., Malcolmson A.M., Folkard M., Prise K.M., and Michael B.D. Direct evidence for a bystander effect of ionizing radiation in primary human fibroblasts. Brit J Cancer 84 (2001) 674-679
105. 211At]MABG. Bioorg Med Chem 15 (2007) 3430-3436